| Outcome | Trial, n | Study name(s) merged | SGLT2i, n | Placebo, n | MD [95%CI] | I2, % | p |
---|---|---|---|---|---|---|---|---|
Only patients with T2DM and renal impairment | SCr, mg/dL | 2 | Haneda 2016 [15] Kashiwagi 2015Â A [16] | 213 | 96 | 0.03 [0.01, 0.05] | 0 | 0.003 |
 | eGFR, mL/min/1.73 m2 | 3 | Haneda 2016 [15] Kashiwagi 2015 A [13] Wada 2022 [10] | 340 | 220 | -1.00 [-3.04, 1.03] | 66 | 0.33 |
Only patients with T2DM and normal renal function | SCr, mg/dL | 8 | Inagaki 2014 [20] Kaku 2014 [21] Kashiwagi 2015B [17] Kashiwagi 2015Â C [18] Kashiwagi 2015D [19] Seino 2014Â A [22] Seino 2014B [23] Seino 2014Â C [24] | 1138 | 508 | 0.01 [0.00, 0.02] | 0 | 0.008 |
 | eGFR, mL/min/1.73 m2 | 6 | Kaku 2014 [21] Kaku 2021 [13] Kashiwagi 2015B [17] Kashiwagi 2015 C [18] Kashiwagi 2015D [19] Seino 2018 [14] | 715 | 374 | -1.43 [-2.48, -0.37] | 1 | 0.008 |
Only patients with T2DM treated with a SGLT2i as monotherapy | SCr, mg/dL | 6 | Inagaki 2014 [20] Kaku 2014 [21] Kashiwagi 2015D [19] Seino 2014Â A [22] Seino 2014B [23] Seino 2014Â C [24] | 876 | 379 | 0.01 [0.00, 0.02] | 0 | 0.02 |
 | eGFR, mL/min/1.73 m2 | 2 | Kaku 2014 [21] Kashiwagi 2015D [19] | 226 | 115 | -2.97 [-5.12, -0.81] | 0 | 0.007 |